Kyowa Kirin Co., Ltd. · TSE:4151
Kyowa Kirin — Merger or Acquisition (November 2024)
12 slides from Kyowa Kirin's merger presentation, Nov 21, 2024
Slide 1: Agreement for Global Strategic Collaboration with Kura Oncology to Develop and Commercialize Ziftomenib
Agreement for Global Strategic Collaboration with Kura Oncology to Develop and Commercialize Ziftomenib
Slide 2: Forward-looking statements disclaimer
This document contains certain forward-looking statements relating to such items as the company’s (including its domestic and overseas subsidiaries) forecasts, targets and plans. These forward-looking statements are based upon information available to the company at the present time and upon reasona
Slide 3: Agenda
Agenda Agreement for Global Strategic Collaboration with Kura Oncology to Develop and Commercialize Ziftomenib Managing Executive Officer, Chief Strategy Officer Yasuo Fujii Q&A Director of the Board, Senior Managing Executive officer and Chief Medical Officer Takeyoshi Yamashita, Ph.D. Managing Exe
Slide 4: License agreement for ziftomenib
License agreement for ziftomenib To strengthen our pipeline in the intractable hematological diseases/hemato oncology and rare diseases, Kyowa Kirin has entered into a license agreement with Kura Oncology for the development and commercialization of ziftomenib ◼ Strategic partnership agreement signe
Slide 5: Story for Vision 2030
Story for Vision 2030 Strategies for creating and delivering life-changing value Disease Science Value Global deployment of delivery on products developed by Focus disease areas: bone & mineral, intractable taking full advantage of our own hematological diseases/hemato oncology, and rare diseases th
Slide 6: Ziftomenib - Collaboration with Kura
Ziftomenib ‐ Collaboration with Kura ‐ US ex- US • Kura leads development Development • Share global development cost • Kyowa Kirin leads development • Kura funds development costs (~2028) Commercialization • Kyowa Kirin commercializes and books sales • Kura books sales • 50/50 profit share Sales Ro
Slide 7: Overview: estimated new AML cases in the United States
OVERVIEW • There are an estimated 20,800 new cases of AML in the United States in ESTIMATED NEW CASES 20241 IN THE UNITED STATES FOR 2024 • AML continues to carry a poor prognosis, where there remains a significant unmet need for additional treatments with durable efficacy AML1 and greater tolerabil
Slide 8: NPM1m: One of the Most Common AML Mutations and an Important Driver Mutation
NPM1m: ONE OF THE MOST COMMON AML MUTATIONS AND AN IMPORTANT DRIVER MUTATION IN THE MENIN COMPLEX • NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend expedited testing for NPM1m at diagnosis to NPM1m is present in up to inform prognosis and guide treatment 35% of AML cases,
Slide 9: Ziftomenib Targets the Menin-KMT2A Pathway, A Foundational Target in AML
Ziftomenib Targets the Menin-KMT2A Pathway, A Foundational Target in AML • NPM1-m and KMT2A-r drive overexpression of HOXA9/MEIS1 genes, critical for transformation to AML • KMT2A(MLL) sits upstream from major AML targets (i.e., FLT3, BCL2, IDH1/2, DNMT3A) • KMT2A(MLL)-dependent genes contribute to
Slide 10: Ziftomenib Demonstrates Potential to Become a Cornerstone of AML Therapy
Ziftomenib Demonstrates Potential to Become a Cornerstone of AML Therapy Targets foundational mutations in up to 50% of AML cases • Compelling clinical data support frontline opportunity • Good tolerability profile, enabling continuous administration in combination with SOC • Combinations appear to
Slide 11: Kyowa Kirin Co., Ltd. Corporate Communications Dept., IR Group
Kyowa Kirin Co., Ltd. Corporate Communications Dept., IR Group +81-3-5205-7206 / ir@kyowakirin.com
Slide 12: Strategic Investment: For successful creation and delivery of life-changing value
Strategic Investment ～For successful creation and delivery of life-changing value Licensing-in and M&A investments to strengthen the portfolio ● Development pipeline with synergies with Crysvita 2021-2025 Cash Allocation* and Poteligeo ◆Bone, Mineral ◆Hematologic oncology ● Implementing the strength